BUND FINANCE › Stocks › INSM
Insmed Incorporated (INSM)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +8.23% above its 50-day average.
- It is -2.47% below its 200-day average (long-term downtrend).
- It sits at 24% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$188.5M | US$245.4M | US$305.2M | US$363.7M | US$606.4M |
| Net income | −US$434.7M | −US$481.5M | −US$749.6M | −US$913.8M | −US$1.3B |
| EPS (diluted) | -3.88 | -3.91 | -5.34 | -5.57 | -6.41 |
| Gross margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.4% |
| Operating margin | -199.0% | -186.4% | -232.5% | -241.5% | -194.0% |
| Net margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| Free cash flow | −US$370.6M | −US$410.3M | −US$549.5M | −US$705.8M | −US$967.6M |
| Total debt | US$612.3M | US$1.2B | US$1.2B | US$1.3B | US$768.2M |
| Cash | US$716.8M | US$1.1B | US$482.4M | US$555.0M | US$510.4M |
Compound annual growth: revenue 33.9% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | — | 27.1x |
| EV / EBITDA | — | — | 16.5x |
| Operating margin | -35.6% | — | 3.6% |
| Net margin | -39.9% | — | -0.0% |
| Debt / equity | 2.07 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Insmed Incorporated
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice